1. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases 
Laura Park-Wyllie, PharmD, PhD, Judy van Stralen, MD, FRCPC, Genaro Castillon, MD, Stephen E. Sherman, PhD, Doron Almagor, MD, FRCPC 
Clinical Therapeutics 
Volume 39, Issue 10, Pages (October 2017)
DOI: /j.clinthera
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
Forest plot comparing reporting rate ratios for therapeutic failure of MPH ER-C/OROS MPH (generic/brand) for the main analysis and sensitivity analyses. MPH ER-C = methylphenidate ER-C (Canadian generic); OROS MPH = OROS methylphenidate (Canadian brand).
Clinical Therapeutics  , DOI: ( /j.clinthera )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
A, Mean dose-corrected plasma methylphenidate (MPH) concentrations over time with the use of MPH extended release (MPH ER-C; generic), Osmotic Release Oral System (ORS-MPH; branded), and MPH sustained release (MPH-SR) (n = 24). B, Mean dose-corrected ratios of plasma methylphenidate concentration over time with MPH ER-C/OROS-MPH, MPH ER-C/MPH-SR, and MPH-SR/OROS-MPH (n = 24). Reproduced with permission.12.
Clinical Therapeutics  , DOI: ( /j.clinthera )
Copyright © 2017 The Authors Terms and Conditions